← Back to patent-cliff list
CAS 1282516-65-7
9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide
Codes: TASE-008
Application context (from source-drug indications)
Breast cancerTaselisibBladder cancerTaselisibMultiple myelomaTaselisibLung cancerTaselisibLiver cancerTaselisibCervical cancerTaselisib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Taselisib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-bromo-2-hydroxybenzaldehyde→5-bromo-2-(1H-imidazol-2-yl)phenol→1,2-dibromoethane→9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine→9-bromo-2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine→9-bromo-2-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine→bis(trimethylsilyl)amine→9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide→1,1-dimethoxy-N,N-dimethylethanamine→9-bromo-2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine→2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanamide
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.